Registry-listed formulations

Gefarnate · chembl:CHEMBL2105085

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    200%(2 trials)
    Terminated
    1(33%)

    Phase Distribution

    Phase 3
    2
    67%
    Phase 2/3
    1
    33%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    2

    Late Stage

    Phase Distribution3 total trials
    Phase 2/3Combined phases
    1(33.3%)
    Phase 3Large-scale testing
    2(66.7%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(1)
    Terminated(1)
    Other(1)

    Detailed Status

    Terminated1
    Completed1
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 2/31 (33.3%)
    Phase 32 (66.7%)

    Trials by Status

    terminated133%
    completed133%
    unknown133%

    Recent Activity

    0 active trials
    Showing 3 of 3
    unknownphase_2_3

    Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

    NCT03610321
    terminatedphase_3

    A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

    NCT00762359
    completedphase_3

    Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

    NCT00787254

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT03610321Phase 2/3

    Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

    Unknown
    NCT00762359Phase 3

    A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

    Terminated
    NCT00787254Phase 3

    Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    3

    External References

    ChEMBL
    CHEMBL2105085

    Names & Codes

    ATC Classification

    A02BX07A02BX77

    Research Codes

    DA 688